Core Viewpoint - Bernstein Liebhard LLP has initiated a securities fraud class action lawsuit against CarMax, Inc. for alleged misrepresentations regarding the company's growth prospects, affecting investors who purchased securities between June 20, 2025, and September 24, 2025 [2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of Maryland on behalf of investors who acquired CarMax securities during the specified period, alleging violations of the Securities Exchange Act of 1934 [2]. - Investors wishing to serve as lead plaintiff must file papers by January 2, 2026, with the option to remain an absent class member if they choose not to take action [3]. Group 2: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its establishment in 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized for its litigation success, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Points - A securities fraud class action lawsuit has been filed against Fiserv, Inc. for alleged violations of the Securities Exchange Act of 1934 [2] - The lawsuit claims that Fiserv and certain senior officers made misrepresentations regarding the Company's initiatives and projects [2] - Investors who purchased Fiserv securities between July 23, 2025, and October 29, 2025, are eligible to participate in the class action [2] Legal Proceedings - The deadline to file as a lead plaintiff in the class action is January 5, 2026 [3] - A lead plaintiff acts on behalf of other class members in directing the litigation, but participation in any recovery does not require serving as lead plaintiff [3] - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3] Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4] - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [4]

Core Viewpoint - Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Synopsys, Inc. related to misrepresentations about the company's Design IP business and its focus on artificial intelligence customers [1][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired Synopsys securities between December 4, 2024, and September 9, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Synopsys and certain senior officers [3]. Group 2: Legal Representation - Investors wishing to serve as lead plaintiff must file papers by December 30, 2025, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [5]. - The law firm has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [6].

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of James Hardie Industries plc (NYSE: JHX)?Did you purchase your shares between May 20, 2025 and August 18, 2025, inclusive?Did you lose money in your investment in James Hardie Industries plc?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX) investors of an upcoming dead ...

Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to undisclosed adverse financial information during the specified class period from February 5, 2025, to July 23, 2025 [1][3]. Summary by Sections Class Action Details - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and investors who acquired Molina securities during the class period have until December 2, 2025, to seek lead plaintiff status [1][2]. - The law firm Robbins Geller Rudman & Dowd LLP is representing the plaintiffs in this case [7]. Allegations Against Molina Healthcare - The lawsuit alleges that Molina Healthcare failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [3]. - It is claimed that Molina's near-term growth relied on reduced utilization of various healthcare services, which was not communicated to investors [3]. Financial Performance and Impact - On July 7, 2025, Molina reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - Following this announcement, Molina's stock price declined significantly, reflecting investor concerns over the company's financial guidance being cut by 10.2% at the midpoint for fiscal year 2025 [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and attributing this to a challenging medical cost trend environment [5]. The stock price fell nearly 17% after this news [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud, alleging that the company misled investors about the reliability and accuracy of its continuous glucose monitoring systems, leading to significant stock declines [2][4]. Company Overview - DexCom, Inc. specializes in manufacturing continuous glucose monitoring (CGM) systems, including the Dexcom G6 and G7 models [5]. Allegations and Issues - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7, which compromised the accuracy of the devices and posed potential health risks to customers [6]. - The company allegedly prioritized cost-cutting over safety, ignoring critical safety issues [6]. Stock Performance and Impact - DexCom's stock experienced significant declines due to revelations about quality issues: - On March 7, 2025, the stock fell by $7.12 per share (over 9%) following an FDA warning letter regarding manufacturing concerns [7]. - After the FDA's public disclosure on March 25, 2025, the stock dropped another $3.19 per share (over 4%) [8]. - A report published on September 18, 2025, led to a nearly 12% decline, with the stock dropping $8.99 per share over two trading days [9].

Core Viewpoint - Stride, Inc. is under investigation for potential violations of federal securities laws, following a significant drop in its stock price due to poor customer experiences stemming from platform changes [1][3][5]. Group 1: Company Performance - Stride, Inc. reported "record demand" for its products and services during the relevant period, claiming that customers were choosing its offerings in increasing numbers [3]. - The company faced backlash due to unpopular platform changes that negatively impacted customer experiences, leading to a decline in student enrollment [4][5]. - Stride estimated a loss of approximately 10,000-15,000 enrollments due to these issues, resulting in a "muted" outlook compared to previous years [5]. Group 2: Stock Market Reaction - On October 28, 2025, Stride disclosed that its growth rate did not meet expectations, which led to a drastic stock price drop of $83.48 per share, or over 54%, from $153.53 to $70.05 within a day [6].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud, following a significant drop in stock price attributed to alleged misrepresentations regarding its Design IP business [2][4]. Company Overview - Synopsys, Inc. specializes in design automation software products used for designing and testing integrated circuits. Its Design IP segment has been the fastest-growing area, increasing from 25% of revenue in 2022 to 31% in 2024 [5]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline. Net income was reported at $242.5 million, a 43% year-over-year decline [7]. Customer Dynamics - The company previously claimed that customers relied on its IP to minimize integration risk and expedite time to market. However, it was revealed that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business [6]. Stock Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys's stock price fell from $604.37 to $387.78 per share, a decline of nearly 36% in one day [7].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab, which led to a significant drop in stock price [1][3][7]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [4]. Group 2: Allegations and Claims - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [3]. - Allegations include that MoonLake misled investors regarding the clinical data and the Nanobody structure of sonelokimab, which purportedly did not provide a superior clinical benefit compared to competitors [5][6]. Group 3: Stock Performance and Impact - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [7].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][4]. Company Overview - Beyond Meat specializes in plant-based meat alternatives and underwent a global operations review in late 2023, during which it depreciated certain long-lived assets [3]. Stock Performance - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to its long-lived assets, which was anticipated to be material. Following this announcement, the stock price fell approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [5]. - The company further delayed its earnings announcement for Q3 2025 on November 3, 2025, due to the need for additional time to complete the impairment review, leading to a significant decline in stock price on that trading day [6].